<!DOCTYPE html>
<html lang="en">

<head>
    <title>
        
            OmniSeq Page 3
        
    </title>

    <style>

    </style>
    <link href="https://fonts.googleapis.com/css?family=Lato&display=swap" rel="stylesheet">

     <link rel="stylesheet" type="text/css" href="/Users/mglynias/Desktop/PycharmProjects/nova/static/css/main.css">
</head>

<body>
<img src="/Users/mglynias/Desktop/PycharmProjects/nova/static/IntegratedOncology.jpg" width="150" />

<img class="Omniseq_logo" src="/Users/mglynias/Desktop/PycharmProjects/nova/static/omniseqCdx_logo.png" />

<div class="Section_Header">THERAPY DETAILS FOR THE TESTED SPECIMEN</div>
<div class="Section_Subhead">Colorectal Cancer</div>
<div class="Vertical_Spacer_10"> </div>

<div class="Details_Wrapper">
    
    
    
    
   <div>
        EGFR amp
        
    </div>
    <div>EGFR (HER1), epidermal growth factor receptor, is a tyrosine kinase receptor, which activates RAS/RAF/MEK and PI3K/AKT/mTOR pathways, leading to increased cell proliferation and growth (PMID: 24312144). EGFR activating mutations, amplification, and overexpression are found in a variety of tumors, including non-small cell lung cancer (PMID: 26609494, PMID: 30284706) and colorectal cancer (PMID: 30243897), and the EGFRvIII variant is commonly found in glioblastoma (PMID: 30201736).</div>
    
</div>

    <div class="Strong_Header">STRONG - CDx (Level IA)</div>
    <div class="Therapy_Details_Wrapper">
        <div style="background-color: lightgray">Therapy</div>
        <div style="background-color: lightgray">Availability</div>
        <div style="background-color: lightgray">Efficacy</div>
        
            <div>panitumumab</div>
            <div>-</div>
            <div>In a Phase III trial that supported FDA approval, Vectibix (panitumumab) demonstrated clinical efficacy only in colorectal cancer patients with wild-type KRAS, resulting in a median progression-free survival of 12.3 weeks, compared to 7.3 weeks with best supportive care (BSC), improved overall survival (HR=0.67), and a response rate of 17% (21/141) (PMID: 18316791; NCT00113763).</div>
        
    </div>





   <div class="Emerging_Header">EMERGING - Clinical Trials (Level IIC)</div>
  <div class="Therapy_Details_Wrapper">
        <div style="background-color: lightgray">Therapy</div>
        <div style="background-color: lightgray">Availability</div>
        <div style="background-color: lightgray">Efficacy</div>
        
            <div>depatuxizumab mafodotin</div>
            <div>-</div>
            <div>In a Phase I/II trial, Depatuxizumab mafodotin (ABT-414) treatment resulted in partial response in 1.8% (1/56) and stable disease in 23% (13/56) of patients with advanced solid tumor harboring EGFR amplification, overexpression, or mutated EGFR variant III (PMID: 29533458; NCT01741727).</div>
        
  </div>

<div class="Cap_Asco_Blurb">
    AMP/CAP/ASCO Evidence Levels: IA: FDA approved or included in professional guidelines; IB: well-powered studies with expert consensus; IIC: FDA-approved therapies for other tumor types, investigational therapies or published studies with consensus; IID: published studies without consensus.
</div>
<div class="Vertical_Spacer_12"></div>


<div class="Details_Wrapper">
    
    
    
    
   <div>
        ERBB2 amp
        
    </div>
    <div>ERBB2 (HER2), erb-b2 receptor tyrosine kinase 2, is an EGFR receptor tyrosine kinase that activates PI3K-AKT-mTOR and RAS-RAF-MEK-ERK pathways, therefore regulating growth and transformation (PMID: 17471238). ERBB2 (HER2) amplification, overexpression, and activation has been implicated in several tumor types (PMID: 17471238).</div>
    
</div>



   <div class="Moderate_Header">MODERATE - Phase II clinical trial evidence (Level IB)</div>
  <div class="Therapy_Details_Wrapper">
        <div style="background-color: lightgray">Therapy</div>
        <div style="background-color: lightgray">Availability</div>
        <div style="background-color: lightgray">Efficacy</div>
        
            <div>neratinib</div>
            <div>-</div>
            <div>In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 8.3% (1/12), and a median progression-free survival of 1.8 months in patients with colorectal cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).</div>
        
            <div>pertuzumab + trastuzumab</div>
            <div>-</div>
            <div>In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 38% (14/37, all partial response) and stable disease lasting over 120 days in 11% (4/37) of patients with colorectal cancer harboring ERBB2 (HER2) amplification or overexpression, with a median duration of response of 11 months (PMID: 29320312; NCT02091141).</div>
        
            <div>afatinib</div>
            <div>-</div>
            <div>In a Phase II trial, Gilotrif (afatinib), demonstrated safety and efficacy in various advanced solid tumor patients with ERBB2 (HER2) amplification (PMID: 23775486).</div>
        
            <div>ado-trastuzumab emtansine</div>
            <div>-</div>
            <div>In a Phase II (MATCH) trial, Kadcyla (trastuzumab emtansine)  treatment resulted in partial response in 8.1% (3/37) and stable disease in 43% (16/37) of patients with ERBB2 (HER2) amplified non-breast, non-gastric advanced solid tumors, with a 6-month progression-free survival rate of 24.8% (J Clin Oncol 36, 2018 (suppl; abstr 100); NCT02465060).</div>
        
            <div>capecitabine + lapatinib + oxaliplatin</div>
            <div>Off Label</div>
            <div>In a Phase II trial, Tykerb (lapatinib), Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination treatment resulted in a disease control rate of 81.3% (26/32, 7 complete response, 15 partial response, 4 stable disease) in patients with Erbb2 (Her2)-positive (defined as IHC3+ or IHC 2+ with ERBB2 amplification) gastric adenocarcinoma (PMID: 29409051; NCT02015169).</div>
        
  </div>



<div class="Cap_Asco_Blurb">
    AMP/CAP/ASCO Evidence Levels: IA: FDA approved or included in professional guidelines; IB: well-powered studies with expert consensus; IIC: FDA-approved therapies for other tumor types, investigational therapies or published studies with consensus; IID: published studies without consensus.
</div>
<div class="Vertical_Spacer_12"></div>



<div class="Vertical_Spacer_50"></div>
<div class="Footer">
     P-19-01715-150&nbsp;P-20-00000-000 VERSION 1 | Report electronically signed by George Who, MD
    |12/13/2019 10:39 AM ET <br>
    CLIA ID: 33D2098748 | CAP # 9405346 | OmniSeq Inc., 700 Ellicott Street, Buffalo NY 14203 | 1 (800) 781-1259
<img class="Cap_logo" src="/Users/mglynias/Desktop/PycharmProjects/nova/static/cap_logo.png" width="75" />
</div>

</body>

</html>